Beta Bionics, Inc.
BBNX- Exchange
- Nasdaq
- Industry
- Surgical & Medical Instruments & Apparatus
- SEC CIK
- 0001674632
In the last 90 days, Beta Bionics, Inc. insiders filed 0 open-market purchases and 12 sales; 133 institutions reported holding it in 13F filings for Q2 2026, worth $752.4M in total; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $2.50M in total
- 12
- 13F holdersQ2 2026, +6 vs. previous quarter
- 133
- 13F valueReported value at the end of Q2 2026
- $752.4M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding BBNX, Q2 2026
No superinvestor reported holding BBNX at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Beta Bionics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 23, 2026 (view filing)5:40 PM ET | Sep 22 | 1 day | Jones ChristyDirector | SSale | −6.43K | $23.00 | −$147.9K | −24.7%19.6K after | 10b5-1 |
| Sep 18, 2026 (view filing)7:51 PM ET | Sep 9 | 9 days | Hopman MarkChief Commercial Officer | SSale | −36.0K | $18.46 | −$664.6K | −29.0%88.0K after | Amended10b5-1 |
| Sep 17, 2026 (view filing)4:15 PM ET | Sep 16 | 1 day | Hopman MarkChief Commercial Officer | SSale | −30.8K | $20.13 | −$619.6K | −35.3%56.5K after | 10b5-1 |
| Sep 17, 2026 (view filing)4:15 PM ET | Sep 16 | 1 day | Mensinger MikeChief Product Officer | SSale | −2.65K | $22.00 | −$58.3K | −1.5%177.4K after | 10b5-1 |
| Sep 15, 2026 (view filing)4:15 PM ET | Sep 14 | 1 day | Hopman MarkChief Commercial Officer | SSale | −775 | $15.52 | −$12.0K | −0.9%86.4K after | 10b5-1 |
| Sep 4, 2026 (view filing)5:19 PM ET | Sep 3 | 1 day | Saint SeanPresident & CEO | SSale | −5.64K | $20.08 | −$113.3K | −1.4%398.4K after | 10b5-1 |
| Sep 3, 2026 (view filing)6:15 PM ET | Sep 2 | 1 day | Hopman MarkChief Commercial Officer | SSale | −5.33K | $19.11 | −$101.8K | −4.1%124.0K after | |
| Sep 3, 2026 (view filing)6:15 PM ET | Sep 2 | 1 day | Russell Steven JonChief Medical Officer | SSale | −4.22K | $19.11 | −$80.7K | −2.4%169.6K after | |
| Sep 3, 2026 (view filing)6:15 PM ET | Sep 2 | 1 day | Mensinger MikeChief Product Officer | SSale | −4.38K | $19.11 | −$83.6K | −2.4%180.0K after | |
| Sep 3, 2026 (view filing)6:15 PM ET | Sep 2 | 1 day | Feider StephenChief Financial Officer | SSale | −6.67K | $19.11 | −$127.6K | −4.0%159.4K after |
Top 10 13F holders, Q2 2026
The largest institutional positions in Beta Bionics, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Eventide Asset Management, LLC | 6,253,673 | $98.1M | 1.31% | +308,185+5.2% | Added |
| Soleus Capital Management, L.P. | 4,393,714 | $68.8M | 2.37% | +39,213+0.9% | Added |
| Morgan Stanley | 4,266,822 | $66.9M | 0.00% | +39,188+0.9% | Added |
| Sands Capital Ventures, LLC | 3,708,043 | $58.1M | 9.47% | 00.0% | Unchanged |
| BlackRock, Inc. | 3,340,171 | $52.3M | 0.00% | +301,576+9.9% | Added |
| Point72 Asset Management, L.P. | 2,254,683 | $35.3M | 0.05% | −270,357−10.7% | Reduced |
| Vanguard Capital Management LLC | 1,782,346 | $27.9M | 0.00% | +54,369+3.1% | Added |
| Vestal Point Capital, LP | 1,600,000 | $25.1M | 0.59% | −611,518−27.7% | Reduced |
| RTW Investments, LP | 1,500,000 | $23.5M | 0.20% | −500,000−25.0% | Reduced |
| Deerfield Management Company, L.P. (Series C) | 1,324,000 | $20.7M | 0.22% | 00.0% | Unchanged |